Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00779389 · ClinicalTrials.gov registry record · Phase 1
Comparison of Biomarker Modulation by Inhibition of EGFR and/or SRC Family
A Phase 1 study, sponsored by University of Pittsburgh.
- Completed
- Registry status
- Phase 1
- Development phase
- 58
- Enrollment target
NCT00779389 is a Phase 1 study that has completed, run by University of Pittsburgh. The registered enrollment target is 58 participants.
The verdict
NCT00779389, a Phase 1 study, has completed, sponsored by University of Pittsburgh.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 58 participants
- Enrollment target
Study Summary
The central hypothesis to be tested in this study is that dual blockade of EGFR and Src pathways or proteins are distinct compared to inhibition of either kinase alone in head and neck and lung cancers.
Interventions
- DRUG Placebo
- DRUG Erlotinib
- DRUG Dasatinib + Placebo
- DRUG Erlotinib plus Dasatinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 58 participants |
| Start Date | 2009-01 |
| Est. Completion | 2014-02 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00779389
The ClinicalTrials.gov registry entry for NCT00779389 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 58 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Pittsburgh, which has 1,238 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Placebo is the first listed.
NCT00779389 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00779389 about?
NCT00779389 is a clinical study titled "Comparison of Biomarker Modulation by Inhibition of EGFR and/or SRC Family". The central hypothesis to be tested in this study is that dual blockade of EGFR and Src pathways or proteins are distinct compared to inhibition of either kinase alone in head and neck and lung cancers.
What is the current status of trial NCT00779389?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 58 participants. The study started on 2009-01. Estimated completion is 2014-02.
What interventions are being tested in trial NCT00779389?
The interventions under investigation include: Placebo (DRUG), Erlotinib (DRUG), Dasatinib + Placebo (DRUG), Erlotinib plus Dasatinib (DRUG).
Who is sponsoring clinical trial NCT00779389?
This trial is sponsored by University of Pittsburgh, which has 1,238 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.